CD4 CAR T Cells - More Than Helpers

Overview

Journal Nat Cancer

Specialty Oncology

Date 2023 May 29

PMID 37248396

Authors

M Eric Kohler

Terry J Fry

Affiliations

Soon will be listed here.

Citing Articles

Finding a needle in a haystack: functional screening for novel targets in cancer immunology and immunotherapies.

Du Y, Yang Y, Zheng B, Zhang Q, Zhou S, Zhao L Oncogene. 2025; 44(7):409-426.

PMID: 39863748 PMC: 11810799. DOI: 10.1038/s41388-025-03273-8.

CAR T-cell therapy to treat multiple myeloma: current state and future directions.

Reddy S, Hosoya H, Mikkilineni L Cancer Metastasis Rev. 2024; 44(1):14.

PMID: 39625587 DOI: 10.1007/s10555-024-10219-1.

References

Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M . Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature. 2022; 602(7897):503-509. PMC: 9166916. DOI: 10.1038/s41586-021-04390-6. View

Oh D, Fong L . Cytotoxic CD4 T cells in cancer: Expanding the immune effector toolbox. Immunity. 2021; 54(12):2701-2711. PMC: 8809482. DOI: 10.1016/j.immuni.2021.11.015. View

Ridge J, Rosa F, Matzinger P . A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998; 393(6684):474-8. DOI: 10.1038/30989. View

Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lemaitre F . A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol. 2021; 6(57). DOI: 10.1126/sciimmunol.abd4344. View

Borst J, Ahrends T, Babala N, Melief C, Kastenmuller W . CD4 T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018; 18(10):635-647. DOI: 10.1038/s41577-018-0044-0. View

Christopher M, Petti A, Rettig M, Miller C, Chendamarai E, Duncavage E . Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med. 2018; 379(24):2330-2341. PMC: 6322675. DOI: 10.1056/NEJMoa1808777. View

Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G . Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019; 25(4):603-611. DOI: 10.1038/s41591-019-0400-z. View

Walsh Z, Yang Y, Kohler M . Immunobiology of chimeric antigen receptor T cells and novel designs. Immunol Rev. 2019; 290(1):100-113. DOI: 10.1111/imr.12794. View

Boulch M, Cazaux M, Cuffel A, Guerin M, Garcia Z, Alonso R . Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4 CAR T-cell antitumor activity. Nat Cancer. 2023; 4(7):968-983. PMC: 10368531. DOI: 10.1038/s43018-023-00570-7. View

10.

Sommermeyer D, Hudecek M, Kosasih P, Gogishvili T, Maloney D, Turtle C . Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2015; 30(2):492-500. PMC: 4746098. DOI: 10.1038/leu.2015.247. View

11.

Bove C, Arcangeli S, Falcone L, Camisa B, El Khoury R, Greco B . CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. J Immunother Cancer. 2023; 11(1). PMC: 9809278. DOI: 10.1136/jitc-2022-005878. View

12.

Yang Y, Kohler M, Chien C, Sauter C, Jacoby E, Yan C . TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med. 2017; 9(417). PMC: 6944272. DOI: 10.1126/scitranslmed.aag1209. View

13.

Wang D, Aguilar B, Starr R, Alizadeh D, Brito A, Sarkissian A . Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight. 2018; 3(10). PMC: 6012522. DOI: 10.1172/jci.insight.99048. View

14.

Ishii K, Pouzolles M, Chien C, Erwin-Cohen R, Kohler M, Qin H . Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. J Clin Invest. 2020; 130(10):5425-5443. PMC: 7524496. DOI: 10.1172/JCI130059. View